Citations

Showing 10 of 108152 citations.

Contemporary trends in the management of aortic stenosis in the USA
Alkhouli, Mohamad , Aljohani, Sami, Holmes, David R. , Mathew, Verghese, Alkhouli, Mohamad , Alqahtani, Fahad , Ziada, Khaled M.

Mayo Clinic

European Heart Journal | July 25, 2019 | Volume: 41 | Issue: 8 | Pages: 921-928

10.1093/eurheartj/ehz568 | PMID 31408096 Get It

Abstract Aims To assess the contemporary trends in aortic stenosis (AS) interventions in the USA before and after the introduction of transcatheter aortic valve implantation (TAVI). Methods and results We utilized the National-Inpatient-Sample to assess temporal trends in the incidence, cost, and outcomes of AS interventions between 1 January 2003 and 31 December 2016. During the study’s period, AS interventions increased from 96 to 137 per 100 000 individuals > 60 years old, P < 0.001. In-hospital expenditure on AS interventions increased from $2.28 billion in 2003 to $4.33 in 2016 P < 0.001. Among patients who underwent aortic valve replacement, the proportion of TAVI increased from 11.9% in 2012 to 43.2% in 2016 (P < 0.001). Males and Hispanics had lower proportions of TAVI compared with females and White patients. Adjusted in-hospital mortality of isolated SAVR decreased from 5.4% in 2003 to 3.3% in 2016 (P < 0.001), whereas adjusted in-hospital mortality of TAVI decreased from 4.7% in 2012 to 2.2% in 2016, P < 0.001. The incidence of new dialysis, permanent pacemaker implantation, and blood transfusion decreased after both TAVI and SAVR between 2012 and 2016. However, the rate of post-operative stroke did not significantly decrease. Length of stay and cost of hospitalization decreased after both SAVR and TAVI, although the later remained higher with TAVI. Rates of non-home discharge decreased over time after TAVI but remained stable after isolated SAVR. Conclusion This nationwide survey documents the increasing incidence of AS interventions, the rising cost of modern AS care, and the paradigm shift in aortic valve replacement practice in the USA.
Transthyretin amyloidosis in patients with undifferentiated heart failure
Chang, Ian C , AbouEzzeddine, Omar F. , Lin, Grace , Grogan, Martha , AbouEzzeddine, Omar, Scott, Christopher G. , Dispenzieri, Angela , AbouEzzeddine, Omar F

Mayo Clinic

Amyloid | July 25, 2019 | Volume: 26 | Issue: sup1 | Pages: 33-34

10.1080/13506129.2019.1582502 | PMID 31343280 Get It

Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation
Lee, Hyun‐Jung , Kim, Hyung‐Kwan , Jung, Jin‐Hyung , Lee, Heesun , Park, Jun‐Bean , Kim, Yong‐Jin , Ommen, Steve R. , Kim, Hyung-Kwan , Han, Kyungdo , Kim, Hyue Mee

Mayo Clinic

Stroke | July 25, 2019 | Volume: 50 | Issue: 9 | Pages: 2582-2586

10.1161/strokeaha.119.026048 | PMID 31340730 Get It

Background and Purpose— Hypertrophic cardiomyopathy patients with atrial fibrillation are at increased risk of stroke, and anticoagulation is strongly recommended. However, limited data are available regarding the safety and effectiveness of non–vitamin K antagonist oral anticoagulants (NOACs) for primary prevention of stroke. Methods— Using the Korean Health Insurance Review and Assessment Service database, we identified 2397 patients with hypertrophic cardiomyopathy and nonvalvular atrial fibrillation on oral anticoagulation from 2013 to 2016 without history of ischemic stroke, intracranial hemorrhage (ICH), or gastrointestinal bleeding (992 on warfarin and 1405 on NOACs). Inverse probability of treatment weighting with propensity scores was used to balance covariates between treatment groups. Risk for ischemic stroke, ICH, gastrointestinal bleeding, death, and their composite outcome associated with NOAC use was assessed with warfarin use as the reference. Results— During a mean follow-up of 1.6 years, the incidence rates of ischemic stroke, ICH, gastrointestinal bleeding, death, and composite outcome were all significantly lower in the NOAC than in the warfarin group (stroke, 2.8 versus 5.0; ICH, 0.5 versus 1.3; gastrointestinal bleeding, 2.3 versus 3.0; death, 3.0 versus 5.1; composite, 7.5 versus 12.5 events per 100 person-years). NOACs were associated with significantly lower risks of ischemic stroke (hazard ratio [HR], 0.47; 95% CI, 0.32–0.68), ICH (HR, 0.31; 95% CI, 0.14–0.69), gastrointestinal bleeding (HR, 0.62; 95% CI, 0.40–0.96), death (HR, 0.45; 95% CI, 0.31–0.65), and the composite outcome (HR, 0.48; 95% CI, 0.38–0.61) than warfarin. The same trend was observed regardless of the NOAC dose and across various high-risk subgroups. In analysis of individual NOACs, all NOACs were associated with lower risks of ischemic stroke and composite outcome. Conclusions— NOACs showed superior effectiveness and safety versus warfarin in the primary prevention of stroke versus warfarin in real-world Asian hypertrophic cardiomyopathy with atrial fibrillation.
Redefining Cirrhotic Cardiomyopathy for the Modern Era
Izzy, Manhal , VanWagner, Lisa B. , Lin, Grace , Altieri, Mario , Findlay, James Y. , Oh, Jae K. , Watt, Kymberly D. , VanWagner, Lisa B , Lee, Samuel S.

Mayo Clinic

Hepatology | July 25, 2019 | Volume: 71 | Issue: 1 | Pages: 334-345

10.1002/hep.30875 | PMID 31342529 Get It

Cirrhotic cardiomyopathy (CCM) is cardiac dysfunction in patients with end‐stage liver disease in the absence of prior heart disease. First defined in 2005 during the World Congress of Gastroenterology, CCM criteria consisted of echocardiographic parameters to identify subclinical cardiac dysfunction in the absence of overt structural abnormalities. Significant advancements in cardiovascular imaging over the past 14 years, including the integration of myocardial deformation imaging into routine clinical practice to identify subclinical cardiovascular dysfunction, have rendered the 2005 CCM criteria obsolete. Therefore, new criteria based on contemporary cardiovascular imaging parameters are needed. In this guidance document, assembled by a group of multidisciplinary experts in the field, new core criteria based on contemporary cardiovascular imaging parameters are proposed for the assessment of CCM. This document provides a critical assessment of the diagnosis of CCM and ongoing assessment aimed at improving clinical outcomes, particularly surrounding liver transplantation. Key points and practice‐based recommendations for the diagnosis of CCM are provided to offer guidance for clinicians and identify gaps in knowledge for future investigations.
Increased Immune Activation by Pathologic α‐Synuclein in Parkinson's Disease
Grozdanov, Veselin , Bousset, Luc , Hoffmeister, Meike, Bliederhaeuser, Corinna, Meier, Christoph A. , Madiona, Karine , Pieri, Laura , Kiechle, Martin, McLean, Pamela J. , Kassubek, Jan , Behrends, Christian , Ludolph, Albert C. , Weishaupt, Jochen H. , Danzer, Karin M. , Danzer, Karin M , McLean, Pamela J , Hoffmeister, Meike, Melki, Ronald

Mayo Clinic

Annals of Neurology | July 25, 2019 | Volume: 86 | Issue: 4 | Pages: 593-606

10.1002/ana.25557 | PMID 31343083 Get It

Objective Excessive inflammation in the central nervous system (CNS) and the periphery can result in neurodegeneration and parkinsonism. Recent evidence suggests that immune responses in Parkinson disease patients are dysregulated, leading to an increased inflammatory reaction to unspecific triggers. Although α‐synuclein pathology is the hallmark of Parkinson disease, it has not been investigated whether pathologic α‐synuclein is a specific trigger for excessive inflammatory responses in Parkinson disease. Methods We investigated the immune response of primary human monocytes and a microglial cell line to pathologic forms of α‐synuclein by assessing cytokine release upon exposure. Results We show that pathologic α‐synuclein (mutations, aggregation) results in a robust inflammatory activation of human monocytes and microglial BV2 cells. The activation is conformation‐ dependent, with increasing fibrillation and early onset mutations having the strongest effect on immune activation. We also found that activation of immune cells by extracellular α‐synuclein is potentiated by extracellular vesicles, possibly by facilitating the uptake of α‐synuclein. Blood extracellular vesicles from Parkinson disease patients induce a stronger activation of monocytes than blood extracellular vesicles from healthy controls. Most importantly, monocytes from Parkinson disease patients are dysregulated and hyperactive in response to stimulation with pathologic α‐synuclein. Furthermore, we demonstrate that α‐synuclein pathology in the CNS is sufficient to induce the monocyte dysregulation in the periphery of a mouse model. Interpretation Taken together, our data suggest that α‐synuclein pathology and dysregulation of monocytes in Parkinson disease can act together to induce excessive inflammatory responses to α‐synuclein. ANN NEUROL 2019;86:593–606
Building the Regenerative Medicine Workforce of the Future: An Educational Imperative
Wyles, Saranya P. , Terzic, André

Mayo Clinic

Regenerative Medicine | July 25, 2019 | Volume: 14 | Issue: 7 | Pages: 613-615

10.2217/rme-2019-0072 | PMID 31342853 Get It

Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia
Crespi, Joan , Bratbak, Daniel Fossum , Matharu, Manjit , Jamtøy, Kent Are , Matharu, Manjit Singh , Dodick, David W. , Tronvik, Erling

Mayo Clinic

Headache: The Journal of Head and Face Pain | July 25, 2019 | Volume: 59 | Issue: 8 | Pages: 1229-1239

10.1111/head.13608 | PMID 31342515 Get It

Background The sphenopalatine ganglion (SPG) has previously been targeted in trigeminal neuralgia (TN), but its role in this condition has not been established. Objective To investigate the safety of injecting onabotulinumtoxinA (BTA) toward the SPG using the MultiGuide ® in 10 patients with refractory classical TN, and collect preliminary efficacy data. Methods Twenty‐five international units (IU) of BTA were injected toward the SPG in a prospective, open‐label study in 10 patients with refractory classical TN. All patients were recruited and treated on an out‐patient basis at St. Olav's University Hospital in Trondheim (Norway). Primary outcome: adverse events (AEs). Primary efficacy outcome: number of TN attacks at weeks 5‐8 after injection compared to baseline. A treatment responder was predefined as at least 50% reduction in the median number of attacks per day between baseline and weeks 5‐8. Other efficacy outcomes were intensity of attacks (numeric rating scale, 0 to 10) and functional level (1 to 4; 1 best and 4 worst) at weeks 5‐8 after injection compared to baseline. Percentage of the day with concomitant persistent pain was registered at baseline and at weeks 1‐4, 6, 8, and 12 after injection. Patient global impression of change (PGIC) was ascertained at month 3. Results For the primary endpoint, we analyzed data for all 10 patients. For efficacy outcomes we analyzed data for 9 patients (1 patient violated protocol). We registered 13 AEs, none of which were serious. The median number of TN attacks during the 4‐week baseline and weeks 5‐8 after injection was 5.5 (range: 1.0‐51.5) and 5 (range: 0‐225.0), respectively ( P = .401). Four patients were treatment responders. The median intensity of attacks at baseline and weeks 5‐8 after injection was 6 (range: 3.0‐8.5) and 3 (range: 0.0‐9.0) respectively ( P = .024). The median functional level at baseline was 2 (range: 1.0‐3.3) and at month 2, 1 (range 1.0‐4.0; P = .750). Median percentage of the day with concomitant persistent pain was 75% (minimum 37.5%, maximum 100%) at baseline and 18.75% (minimum 0%, maximum 100%) at week 8 ( P = .023). Conclusions Injection of BTA toward the SPG using the MultiGuide ® in patients with TN appears to be safe and well tolerated. This study was negative for the main efficacy endpoint (reduction in the number of attacks from baseline to weeks 5‐8). Further studies examining the role of the SPG in TN are necessary.
CSF Pressure, Volume, and Post‐Dural Puncture Headache: A Case‐Control Study and Systematic Review
Grory, Brian Mac , Butterfield, Richard , Khokar, Babar, Falk, Bryce L., Marks, Lisa , Butterfield, Richard J, Marks, Lisa A., Marks, Lisa A , Smith, Jonathan H. , Mac Grory, Brian

Mayo Clinic

Headache: The Journal of Head and Face Pain | July 25, 2019 | Volume: 59 | Issue: 8 | Pages: 1324-1338

10.1111/head.13602 | PMID 31342523 Get It

Objectives (1) To perform a systematic literature review to evaluate associations between post‐dural puncture headache (PDPH) and opening pressure (OP), closing pressure (CP), and volume of cerebrospinal fluid (V) removed. (2) To perform a case‐control study to evaluate pressure‐volume index (PVI) as a novel risk factor for PDPH. Background According to the International Classification of Headache Diagnoses, 3rd Edition (ICHD‐3), the diagnosis of PDPH requires documentation of intracranial hypotension. However, this remains an unproven concept. Methods A systematic literature review was conducted, searching Cochrane Database of Systematic Reviews, Ovid EMBASE, OVID MEDLINE, Scopus, and Web of Science. Study inclusion required a comparison of headache incidence following a LP as a function of OP, CP, and/or V. A retrospective, case‐control study with 1:1 matching was conducted utilizing ICHD‐3 criteria. Patients with factors that could influence CSF pressure were excluded. Results In our case‐control study, we did not identify a paired difference in either median (95% CI) elastance (0.05 [−0.09, 0.11], P = .503) or PVI (4.53 [−7.98, 19.97], P = .678). We identified 22 references, evaluating V (n = 14), OP (n = 11), and/or CP (n = 4). There was no convincing evidence for an association of PDPH with either OP or CP. A minority of studies documenting an association with V included patients with high‐volume CSF removal, and/or stratified patients by the timing of the headache onset. Conclusions The overall risk of PDPH does not appear to be influenced by OP, CP, V or PVI. PDPH may be related to V in instances of high‐volume removal, and depend on the timing of outcome assessment. Future revision of criteria should consider the existence of immediate and delayed PDPH subtypes, and not presume intracranial hypotension as a mandatory feature.
PERSISTENT PLACOID MACULOPATHY-LIKE FINDINGS IN PATIENTS WITH GIANT CELL ARTERITIS
Starr, Matthew R. , Fairbanks, Aaron M. , Geraets, Ryan D., Chen, John , Pulido, José S. , Chen, John J. , Chen, John J , Starr, Matthew R

Mayo Clinic

RETINAL Cases & Brief Reports | July 24, 2019 | Volume: 15 | Issue: 6 | Pages: 682-687

10.1097/icb.0000000000000894 | PMID 31343560 Get It

Purpose: To describe two patients with giant cell arteritis who presented with macular lesions mimicking persistent placoid maculopathy. Methods: Retrospective case reports. Patient: Two patients, a 74-year-old man and an 85-year-old woman both were diagnosed with biopsy-confirmed giant cell arteritis with vision loss in one eye due to arteritic ischemic optic neuropathy. Both presented many years later with acute vision loss in the remaining eye. Results: Both patients had bilateral retinal whitening in the parafovea, and the second also had sectoral optic disk swelling. On fluorescein angiography, these areas of retinal whitening in both patients were hypofluorescent early with late hyperfluorescence staining. On indocyanine green angiography, there were areas of foveal hypocyanescence bilaterally in both patients that persisted throughout the imaging and were more apparent late. These findings can be seen in patients with bilateral persistent placoid maculopathy. Conclusion: Giant cell arteritis should be included in the differential diagnosis of persistent placoid maculopathy.